MOXI™ is a Sciton non-ablative fractional laser that delivers 1927 nm thulium fiber laser energy in a fractionated pattern — creating microscopic treatment zones in the skin without removing the surface. This controlled injury response triggers the body’s natural repair mechanisms, stimulating cellular turnover, collagen production, and the gradual elimination of pigment and tone irregularities.
Unlike ablative resurfacing — which removes the epidermis entirely — MOXI™ leaves the skin surface intact. Treated microcolumns of tissue initiate healing from within, producing progressive improvement with significantly less downtime and a lower risk profile across Fitzpatrick skin types I–VI.
MOXI™ is frequently described as a maintenance and prevention treatment — ideal for patients in their late 20s through 40s looking to address early photodamage before it becomes entrenched, or for those who want consistent skin quality improvement between more intensive procedures.
All skin types, all year The 1927 nm wavelength and non-ablative delivery make MOXI™ one of the few laser treatments appropriate for darker Fitzpatrick skin types and safe for year-round use, including summer months.
Preventative and corrective Addresses existing tone irregularities and early sun damage while proactively slowing the progression of photodamage, making it as effective for maintenance as it is for correction.
Minimal downtime No open wound, no peeling in the traditional sense. Most patients experience 2–4 days of mild redness and a sandpaper-like texture, MEDs (microscopic epidermal necrotic debris), before the skin clears and reveals improved tone.
Stackable and combinable MOXI™ integrates seamlessly into broader treatment plans, commonly paired with BBL HERO® for the MOXI + BBL Forever Young protocol, or layered with other Sciton treatments for enhanced outcomes.
Targets superficial pigment irregularities, sun spots, early melasma, and post-inflammatory discoloration, improving overall evenness and clarity.
Fractional treatment zones stimulate epidermal renewal and collagen activity, gradually smoothing rough or uneven skin texture.
,Controlled thermal injury triggers neocollagenesis, new collagen production that improves skin density and resilience over the weeks following treatment.
Regular MOXI™ treatments slow the accumulation of photodamage and support long-term skin health, particularly effective when begun before visible aging becomes established.
,Accelerated cellular turnover removes dull, damaged surface cells, leaving skin appearing brighter, more even, and refreshed following the healing phase.
Safe for repeated use across all seasons and skin types, making it a practical option for patients seeking consistent, progressive improvement without significant recovery.
Read about our safety and side effects, as well as the typical treatment protocol.
1. Medical history review, Fitzpatrick skin typing, and photograph documentation of treatment areas.
2. Discussion of treatment settings, expected MEDs response, downtime, and post-care requirements.
3. Topical anaesthetic applied; skin cleansed and prepped. Comfort level confirmed before treatment begins.
4. MOXI™ treatment delivered by the clinician. A warm, prickling sensation is typical during the procedure.
5. Cooling applied post-treatment; gentle moisturizer and mineral SPF applied before departure. Written aftercare and follow-up scheduling provided.
Both use Sciton fractional technology, but MOXI™ is non-ablative — it does not remove the skin surface. HALO™ combines non-ablative and ablative wavelengths for deeper correction and more significant remodeling. MOXI™ is better suited for prevention, maintenance, and patients with early photodamage or minimal downtime availability. HALO™ addresses more established aging, scarring, and texture concerns.
MEDs — microscopic epidermal necrotic debris — are tiny darkened cellular fragments that rise to the skin surface as part of the healing process. They present as a bronzed, rough, or sandpaper-like texture and shed naturally within 3–5 days. They are a normal and expected part of the MOXI™ response — not a side effect.
Initial clarity and brightness are often noticeable within 5–7 days once MEDs shed. Continued improvement in tone, texture, and pigmentation develops over 4–8 weeks as collagen remodeling progresses.
Most patients begin with a series of 3–4 treatments spaced 4–6 weeks apart, followed by maintenance sessions every 3–6 months. Frequency is adjusted based on individual response, skin goals, and lifestyle factors.
Yes — MOXI™ is one of the few laser treatments with a favorable safety profile across all Fitzpatrick skin types, including V and VI, when appropriate settings are selected. A thorough consultation and conservative initial approach are standard practice for higher Fitzpatrick types.
MOXI™ can be performed year-round, including warmer months, provided strict sun avoidance and SPF use are maintained before and after treatment. Tanned or recently sun-exposed skin should not be treated until tone has normalized.
Plan your treatment 2 weeks before you want results to take effect, and at least 6 weeks ahead of any special event for optimal results. Maintain your results with treatments every 3 – 6 months.
